NASDAQ
20.65USD
+1.16 (+5.95%)
We have scored 39 news catalysts on Replimune Group, Inc. (REPL) over the past 12 months. The biggest single-day move next to one of them came Jul 31, 2026, when REPL closed +107.0%: “This Biotech Stock Is Soaring 132% After Key FDA Panel Vote on Skin Cancer Treatment”. Coverage across the window leans negative (average ticker sentiment −0.59). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2B
P/E
—
EPS
—
Beta
0.94
52W range
1.5-21.2599
Day range
19.50–21.26
Open
19.52
Prev close
19.49
Volume
4.7M
Avg volume
3.9M
Dividend
0.00
IPO
2018-07-20
Analysts publish price targets on REPL, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
6 analyst price targets from $9 to $20
as of 2026-09-23
The market is 21% below the median target — more cautious than the analysts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Replimune Group, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Replimune Group, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for REPL: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
The reconstruction
The price sits 21% below the median analyst target and at the 33rd percentile of the published spread, meaning it largely rejects the bullish case for RP1 approval and instead assumes the company's regulatory and legal troubles will keep a lid on value.
What the disagreement turns on
Whether the FDA ultimately approves RP1 in early August despite the prior rejections and the reviewers' critique, and none of the wired data tools can measure or predict a binary regulatory outcome.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $12.96 on 2026-09-23 — the quote has since moved +59%, so read this as a record of what was priced in then, not now.
